Panel: Telesta Bladder Cancer Drug Targeted Wrong Patients
This article was originally published in Scrip
Executive Summary
Telesta Therapeutics Inc.'s experimental drug Mycobacterium phlei cell wall-nucleic acid complex (MCNA) won't get its chance to potentially change the landscape of bladder cancer – or at least, not any time soon – if the FDA takes the advice of its advisory panel, which refused to back the marketing of the medicine for the indication the firm is seeking.
You may also be interested in...
Deal Watch: Ferring Enters New Therapeutic Area With Phase III Sciatica Candidate
Trek Therapeutics expands its HCV pipeline by in-licensing polymerase inhibitor from Medivir. ProMetic gains cash, tax offsets and physical plant by acquiring fellow Canadian firm Telesta for pennies per share, while Cell Medica inks its second academic cancer immunotherapy collaboration of 2016, this time with University College London.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.